| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Combining artesunate with existing antimalarial drugs may improve cure rates, delay emergence of resistance, and reduce transmission. We performed a randomized comparative trial to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in Indonesia. Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalarial drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally, 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0, and 52 patients received sulfadoxine-pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group. Treatment failure rates on day 14 were 0% in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P = 0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P = 0.16). Relative risk of treatment failure at 28 days was 0.3 (95% confidence interval [CI] = 0.1-1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxine-pyrimethamine group than in the sulfadoxine-pyrimethamine group (P = 0.08 and P < 0.0001, respectively). Only 20 (39.2%) of 51 patients treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86.5%) of 52 patients treated with sulfadoxine-pyrimethamine alone (P = 0.000001, relative risk [RR] = 0.4, 95% CI = 0.3-0.6). Gametocyte carriage was lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine (RR = 0.5, 95% CI = 0.2-1.0 on day 7 and RR = 0.5, 95% CI = 0.2-1.1 on day 14). Mild diarrhea, rash, and itching resolved without treatment. Combined artesunate plus sulfadoxine-pyrimethamine resulted in more rapid fever and parasiteclearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.
This article has been cited by other articles:
|
|
 |
|
  T. W. Yeo, I. Rooslamiati, R. Gitawati, E. Tjitra, D. A. Lampah, E. Kenangalem, Y. R. McNeil, R. N. Price, N. M. Anstey, and S. B. Duffull Pharmacokinetics of L-Arginine in Adults with Moderately Severe Malaria Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4381 - 4387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cairo, S. Durand, W. Marquino, C. Cabezas, A. Lachira, F. Quintana, W. Vegas, T. K. Ruebush II, G. Utz, and D. J. Bacon Surveillance for Adverse Drug Reactions to Combination Antimalarial Therapy with Sulfadoxine-Pyrimethamine plus Artesunate in Peru Am J Trop Med Hyg, July 1, 2008; 79(1): 42 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Yeo, D. A. Lampah, R. Gitawati, E. Tjitra, E. Kenangalem, Y. R. McNeil, C. J. Darcy, D. L. Granger, J. B. Weinberg, B. K. Lopansri, et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria J. Exp. Med., October 29, 2007; 204(11): 2693 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. FALADE, F. F. FADERO, C. T. HAPPI, H. O. DADA-ADEGBOLA, G. O. GBOTOSHO, I. AYEDE, A. G. FALADE, A. M. J. ODUOLA, and L. A. SALAKO DIHYDROARTEMISININ SUPPOSITORY IN MODERATELY SEVERE MALARIA: COMPARATIVE EFFICACY OF DIHYDROARTEMISININ SUPPOSITORY VERSUS INTRAMUSCULAR ARTEMETER FOLLOWED BY ORAL SULFADOXINE-PYRIMETHAMINE IN THE MANAGEMENT OF MODERATELY SEVERE MALARIA IN NIGERIAN CHILDREN Am J Trop Med Hyg, January 1, 2007; 76(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Baird Effectiveness of Antimalarial Drugs N. Engl. J. Med., April 14, 2005; 352(15): 1565 - 1577. [Full Text] [PDF]
|
|
|
|
|
|
D. SYAFRUDDIN, P. B. S. ASIH, G. J. CASEY, J. MAGUIRE, J. K. BAIRD, H. S. NAGESHA, A. F. COWMAN, and J. C. REEDER MOLECULAR EPIDEMIOLOGY OF PLASMODIUM FALCIPARUM RESISTANCE TO ANTIMALARIAL DRUGS IN INDONESIA Am J Trop Med Hyg, February 1, 2005; 72(2): 174 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. SUTANTO, S. SUPRIYANTO, P. RUCKERT, PURNOMO, J. D. MAGUIRE, and M. J. BANGS COMPARATIVE EFFICACY OF CHLOROQUINE AND SULFADOXINE-PYRIMETHAMINE FOR UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA AND IMPACT ON GAMETOCYTE CARRIAGE RATES IN THE EAST NUSATENGGARA PROVINCE OF INDONESIA Am J Trop Med Hyg, May 1, 2004; 70(5): 467 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Talisuna, P. Bloland, and U. D'Alessandro History, Dynamics, and Public Health Importance of Malaria Parasite Resistance Clin. Microbiol. Rev., January 1, 2004; 17(1): 235 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tjitra, J. Baker, S. Suprianto, Q. Cheng, and N. M. Anstey Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3947 - 3953. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
